Docetaxel +/- Suramin in 2nd Line Advanced Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2016-06-16
Target enrollment:
Participant gender:
Summary
The overall purpose of the study is to determine whether or not the inclusion of suramin to
standard treatment with docetaxel improves progression-free survival for patients with
advanced non-small cell lung cancer in the second and third line settings.
Phase:
Phase 2
Details
Lead Sponsor:
University of Wisconsin, Madison
Collaborators:
Medical College of Wisconsin Ohio State University Optimum Therapeutics, LLC